EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokollOpen Access

Effects of Supplementation With Genistein on the Progression of Cognitive Decline in Patients With Mild Cognitive Impairment Due to Alzheimer Disease: Protocol for a Randomized Controlled Trial

Effekte einer Genistein-Supplementierung auf das Fortschreiten des kognitiven Abbaus bei Patient:innen mit leichter kognitiver Beeinträchtigung infolge einer Alzheimer-Krankheit: Protokoll für eine randomisierte kontrollierte Studie

Francisco Javier López Román, Manuel Sebastián, Silvia Pérez-Piñero, Ingrid Hernández-Manzano, Olga Laosa-Zafra, Leocadio Rodríguez-Mañas, Francisco José Tarazona-Santabalbina, Consuelo Borrás, José Viña

JMIR Research Protocols · 09.11.2026 · 15 · e98087-e98087

DOI: 10.2196/98087 ↗

Auf einen Blick

Das Protokoll beschreibt eine randomisierte, placebokontrollierte Studie zu oralem Genistein bei MCI infolge Alzheimer-Krankheit. Geprüft wird, ob sich kognitive Verschlechterung und Amyloid-Belastung verändern.

Fragestellung

Wirkt orale Genistein-Supplementierung im Vergleich zu Placebo auf den kognitiven Abbau bei MCI infolge Alzheimer-Krankheit?

Methode

Multizentrische, randomisierte, doppelblinde, placebokontrollierte Studie; Erwachsene ab 50 Jahren; 1:1 zu Genistein 200 mg/Tag oder Placebo für 18 Monate.

Ergebnisse

Primärer Endpunkt ist die Veränderung der iADRS-Skala. Sekundär werden weitere neuropsychologische Maße, Amyloid-Belastung per 18 F-flutemetamol-PET, Plasma-Biomarker und Sicherheit erhoben.

Einschränkungen

Es handelt sich um ein Protokoll; Ergebnisse liegen noch nicht vor.

Schlussfolgerung der Autor:innen

Die Studie soll Evidenz dazu liefern, ob Genistein den kognitiven Abbau verlangsamen und die Amyloid-Belastung senken kann.

Kernaussagen

  • Protokoll einer randomisierten, doppelblinden, placebokontrollierten Studie
  • Genistein 200 mg/Tag vs. Placebo über 18 Monate
  • Primär: Veränderung der iADRS-Skala

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JMIR Research Protocols, online erschienen am 09.11.2026. Verfasst von Francisco Javier López Román und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Exercise Physiology, Faculty of Medicine, Universidad Católica de Murcia, Avenida de los Jerónimos, Murcia, 30107, Spain, +34 968278157…. Hauptthemen laut MEDLINE: Genistein, Alzheimer Disease, Cognitive Dysfunction, Dietary Supplements. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mild cognitive impairment (MCI) may represent a prodromal stage of Alzheimer disease, but interventions to delay progression remain limited. Genistein is a phytoestrogenic isoflavone with potential effects on several pathways implicated in Alzheimer disease. We previously showed that genistein reverses cognitive decline and lowers brain amyloid β (Aβ) in the Aβ precursor protein/presenilin 1 double transgenic (AβPP/PS1) model of Alzheimer disease.

Objective

The study aimed to evaluate whether oral genistein supplementation affects cognitive decline in patients with MCI due to Alzheimer disease, compared with a placebo, and to assess its effects on brain amyloid burden and plasma biomarkers.

Methods

This multicenter, randomized, double-blind, placebo-controlled trial will include adults aged 50 years or older with MCI due to Alzheimer disease. Participants will be randomized 1:1 to genistein (200 mg/day) or a maltodextrin-based placebo for 18 months. The primary outcome is change in the Integrated Alzheimer’s Disease Rating Scale (iADRS) score. Secondary outcomes include other neuropsychological measures, amyloid burden measured by 18 F-flutemetamol positron emission tomography, plasma Alzheimer disease biomarkers, and safety. Outcomes will be assessed at baseline, midstudy, and study completion. Analyses are planned in the intention-to-treat and per-protocol populations using repeated-measures analysis of variance, with time as the within-participant factor, treatment group as the between-participant factor, and study site as a covariate.

Results

Funding for the study began in January 2024 and was provided by Trugon Investigaciones (AIE) through a grant to the Chair of Geroscience at Universidad Católica de Murcia. Data collection began in July 2026 and is projected to conclude in January 2029, consistent with the estimated 30-month study duration. Enrollment is expected to last approximately 9 months. As of August 5, 2026, a total of 4 participants had been recruited. Data analysis has not begun and will start after the final participant completes follow-up. Results are expected to be published in late 2029.

Conclusions

This trial will provide evidence on whether genistein supplementation may help slow cognitive decline and reduce amyloid burden in patients with MCI due to Alzheimer disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GenisteinAlzheimer DiseaseCognitive DysfunctionDietary SupplementsHumansDouble-Blind MethodRandomized Controlled Trials as TopicDisease ProgressionMulticenter Studies as TopicFemaleAgedMaleMiddle AgedBiomarkers

Stichwörter der Autor:innen

Alzheimer diseaseamyloid-betadementiagenisteinmild cognitive impairmentneuropsychological testsrandomized controlled trialsoy isoflavones

Substanzen

GenisteinBiomarkers

Autor:innen und Institutionen

  • Department of Exercise Physiology, Faculty of Medicine, Universidad Católica de Murcia, Avenida de los Jerónimos, Murcia, 30107, Spain, +34 968278157 ext 157.
  • Primary Care Research Group, Instituto Murciano de Investigación Biosanitaria, Murcia, Spain.
  • Faculty of Medicine, Universidad Católica de Murcia, Av. de los Jerónimos, 135, Guadalupe (Murcia), 30107, Spain, +34 968 278 157.
  • Foundation for Biomedical Research, Hospital Universitario de Getafe, Madrid, Spain.
  • Department of Geriatrics, Hospital Universitario de Getafe, Madrid, Spain.
  • Spanish Society of Geriatrics and Gerontology (SEGG), Madrid, Spain.

Zitieren

APA

López Román, F. J., Sebastián, M., Pérez-Piñero, S., Hernández-Manzano, I., Laosa-Zafra, O., Rodríguez-Mañas, L., Tarazona-Santabalbina, F. J., Borrás, C., & Viña, J. (2026). Effects of Supplementation With Genistein on the Progression of Cognitive Decline in Patients With Mild Cognitive Impairment Due to Alzheimer Disease: Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 15, e98087-e98087. https://doi.org/10.2196/98087

Vancouver

López Román FJ, Sebastián M, Pérez-Piñero S, Hernández-Manzano I, Laosa-Zafra O, Rodríguez-Mañas L, et al. Effects of Supplementation With Genistein on the Progression of Cognitive Decline in Patients With Mild Cognitive Impairment Due to Alzheimer Disease: Protocol for a Randomized Controlled Trial. JMIR Research Protocols. 2026;15:e98087-e98087. doi:10.2196/98087

BibTeX
@article{LpezRomn2026,
  author = {López Román, Francisco Javier and Sebastián, Manuel and Pérez-Piñero, Silvia and Hernández-Manzano, Ingrid and Laosa-Zafra, Olga and Rodríguez-Mañas, Leocadio and Tarazona-Santabalbina, Francisco José and Borrás, Consuelo and Viña, José},
  title = {Effects of Supplementation With Genistein on the Progression of Cognitive Decline in Patients With Mild Cognitive Impairment Due to Alzheimer Disease: Protocol for a Randomized Controlled Trial},
  journal = {JMIR Research Protocols},
  year = {2026},
  volume = {15},
  pages = {e98087--e98087},
  doi = {10.2196/98087}
}
Kostenlos starten →